Actions
  • shareshare
  • link
  • cite
  • add
add
Research data . Clinical Trial . 2008

JACTAX LD Drug Eluting Stent Trial

Grube, Eberhard;
Open Access
Published: 16 Sep 2008
Publisher: nct
Abstract

The JACTAX Drug Eluting Stent has been designed to minimize the amount of polymer in contact with the vessel surface, thus potentially reducing the incidence of untoward side effects. The Juxtaposed Ablumenal Coating Process is capable of exclusive coating on the ablumenal side of pre-mounted bare metal stents. Juxtaposed Ablumenal Coating is a proprietary formulation containing a bioerodable polymer. The combination of the Juxtaposed Ablumenal Coating Process and Juxtaposed Ablumenal Coating create a unique microstructure surface, and reduces the amount of required polymer.

Prospective, multi-center, randomized trial. A maximum of 130 patients will be enrolled, in a 2:1 ratio to receive either the JACTAX LD stent or the TAXUS™ Libertè™ stent to evaluate the efficacy of the product.

Download from
lock_open
OpenTrials
Clinical Trial . 2008
Providers: OpenTrials
moresidebar